|
|
Vaccine Detail
|
BBV154 |
| Vaccine Information |
- Vaccine Name: BBV154
- Target Pathogen: SARS-CoV-2
- Target Disease: COVID-19
- Manufacturer: Bharat Biotech
- Vaccine Ontology ID: VO_0005227
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Immunization Route: Nasal spray
|
| Host Response |
|
Human Response
- Vaccination Protocol: induces high levels of neutralizing antibodies, promotes systemic and mucosal immunoglobulin A (IgA) and T cell responses, and almost entirely prevents SARS-CoV-2 infection in both the upper and lower respiratory tracts. PubMed ID: 32931734 (Hassan et. al 2020)
- Immune Response: This study showed that the vaccine induced in humans high levels of neutralizing antibodies, promotes systemic and mucosal immunoglobulin A (IgA) and T cell responses, and almost entirely prevents SARS-CoV-2 infection in both the upper and lower respiratory tracts (PubMed ID: 32931734) (Hassan et. al 2020).
Human Response
- Description: A clinical trial on this vaccine, titled "Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19", is reported: NCT04751682 (https://clinicaltrials.gov/ct2/show/NCT04751682) (NCT04751682).
|
| References |
Hassan et. al 2020: Hassan AO, Kafai NM, Dmitriev IP, Fox JM, Smith BK, Harvey IB, Chen RE, Winkler ES, Wessel AW, Case JB, Kashentseva E, McCune BT, Bailey AL, Zhao H, VanBlargan LA, Dai YN, Ma M, Adams LJ, Shrihari S, Danis JE, Gralinski LE, Hou YJ, Schafer A, Kim AS, Keeler SP, Weiskopf D, Baric RS, Holtzman MJ, Fremont DH, Curiel DT, Diamond MS. A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. . 2020; ; . [PubMed: 32931734].
NCT04751682: Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19 [https://clinicaltrials.gov/ct2/show/NCT04751682]
|
|
